- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for accrued license payments.

+ References

No definition available.

+ Details

Name:	anvs_AccruedLicensePaymentsCurrent
Namespace Prefix:	anvs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The option price at which the license agreement may be bought out by the Company under the terms of the amended license agreement.

+ References

No definition available.

+ Details

Name:	anvs_BuyOutOptionOptionPrice
Namespace Prefix:	anvs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of consideration to be paid by the Company upon the attainment of a milestone as defined in the amended license agreement.

+ References

No definition available.

+ Details

Name:	anvs_CommitmentsMilestonePayment
Namespace Prefix:	anvs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The cumulative number of milestones achieved.

+ References

No definition available.

+ Details

Name:	anvs_CumulativeNumberOfMilestonesAchieved
Namespace Prefix:	anvs_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

The amount of minimum annual commitment which may be deferred until the Company raises the equity financing level as defined in the amended license agreement.

+ References

No definition available.

+ Details

Name:	anvs_LicenseAgreementDeferrableMinimumAnnualCommitment
Namespace Prefix:	anvs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The minimum amount of annual commitment under the terms of a license agreement.

+ References

No definition available.

+ Details

Name:	anvs_LicenseAgreementMinimumAnnualCommitment
Namespace Prefix:	anvs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The period of advance notice required to terminate the license agreement.

+ References

No definition available.

+ Details

Name:	anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination
Namespace Prefix:	anvs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The term of the license agreement.

+ References

No definition available.

+ Details

Name:	anvs_LicenseAgreementTermOfAgreement
Namespace Prefix:	anvs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The threshold amount of equity financing the Company must raise to end deferral of the minimum annual commitment under the terms of the amended license agreement.

+ References

No definition available.

+ Details

Name:	anvs_LicenseAgreementThresholdAmountOfEquityFinancing
Namespace Prefix:	anvs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- References

No definition available.

+ Details

Name:	anvs_LicenseAgreementsAbstract
Namespace Prefix:	anvs_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The percentage of net sales of licensed products used to calculate royalties payable under the terms of the amended licensing agreement.

+ References

No definition available.

+ Details

Name:	anvs_LicensedProductsPercentageOfNetSalesUsedToCalculateRoyaltiesPayable
Namespace Prefix:	anvs_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The percentage of reduction in royalties payable if a third-party license is required.

+ References

No definition available.

+ Details

Name:	anvs_LicensedProductsPercentageOfReductionInRoyaltiesPayableIfThirdPartyLicenseIsRequired
Namespace Prefix:	anvs_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The percentage of sublicense income to be paid in addition to royalty payments under the terms of the amended license agreement.

+ References

No definition available.

+ Details

Name:	anvs_LicensedProductsPercentageOfSublicenseIncomeToBePaidInAdditionToRoyaltyPayments
Namespace Prefix:	anvs_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount paid during the reporting period for deferred license commitments.

+ References

No definition available.

+ Details

Name:	anvs_PaymentsForDeferredLicenseCommitments
Namespace Prefix:	anvs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of one-time non-refundable fee paid by the Company at the initiation of a licensing agreement.

+ References

No definition available.

+ Details

Name:	anvs_PaymentsForLicenseAgreementNonRefundableInitialFee
Namespace Prefix:	anvs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=anvs_HorizonTherapeuticsPlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=anvs_LicenseAgreementTermsAmendedMay2012Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=anvs_ScenarioBuyOutOptionIfExercisedOnOrAfterCommencementOfFirstPhaseTwoClinicalTrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=anvs_ScenarioBuyOutOptionIfExercisedPriorToCommencementOfFirstPhaseTwoClinicalTrialAndPriorToCommencementOfFirstPhaseThreeClinicalTrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=anvs_ScenarioBuyOutOptionIfExercisedPriorToCommencementOfFirstPhaseThreeClinicalTrialAndPriorToFilingOfNewDrugApplicationU.s.FoodAndDrugAdministrationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=anvs_ScenarioBuyOutOptionIfExercisedOnOrAfterFilingOfNewDrugApplicationForFirstLicensedProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=anvs_CommencementOfPhaseTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=anvs_CommencementOfPhaseThreeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=anvs_FilingOfNewDrugApplicationOrEquivalentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=anvs_RegulatoryApprovalUnitedStatesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=anvs_RegulatoryApprovalOutsideUnitedStatesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies - License Agreement (Details)	1 Months Ended		12 Months Ended
	May 31, 2012 USD ($)	Nov. 30, 2008 USD ($)	Dec. 31, 2020 USD ($) item	Dec. 31, 2019 USD ($)
License Agreements
Accrued license payments			$ 3,833	$ 506,000
License Agreement
License Agreements
Payments in in satisfaction of deferred annual fees			494,000
License Agreement \| Horizon Therapeutics, PLC
License Agreements
One-time non-refundable fee		$ 50,000
Minimum annual commitment		$ 40,000
Amended License Agreement
License Agreements
Deferrable minimum annual commitment	$ 46,000
Threshold amount of equity financing	$ 2,000,000
Accrued license payments			$ 3,833	$ 506,000
Amended License Agreement \| Horizon Therapeutics, PLC
License Agreements
Number of milestones achieved \| item			0
Percentage of net sales used to calculate royalties payable			5.75%
Percentage of reduction in royalties payable if third-party license is required			50.00%
Percentage of sublicense income to be paid in addition to royalty payments			9.20%
Period for advance notice of termination			90 days
Term of license agreement			10 years
Amended License Agreement \| Horizon Therapeutics, PLC \| Exercise of by-out option on or after commencement of first Phase II clinical trial
License Agreements
Buy-out option price			$ 500,000
Amended License Agreement \| Horizon Therapeutics, PLC \| Exercise of by-out option prior to commencement of first Phase II clinical trial and prior to the commencement of the first Phase III clinical trial
License Agreements
Buy-out option price			1,000,000
Amended License Agreement \| Horizon Therapeutics, PLC \| Exercise of by-out option prior to commencement of first Phase III clinical trial and prior to the filing of a NDA with the FDA
License Agreements
Buy-out option price			5,000,000
Amended License Agreement \| Horizon Therapeutics, PLC \| Exercise of by-out option on or after the filing of a NDA for the first licensed product
License Agreements
Buy-out option price			8,000,000
Amended License Agreement \| Horizon Therapeutics, PLC \| Commencement of Phase II
License Agreements
Amount of milestone payment			230,000
Amended License Agreement \| Horizon Therapeutics, PLC \| Commencement of Phase III
License Agreements
Amount of milestone payment			575,000
Amended License Agreement \| Horizon Therapeutics, PLC \| Filing of an NDA for Regulatory Approval (or equivalent in Europe or Japan)
License Agreements
Amount of milestone payment			1,150,000
Amended License Agreement \| Horizon Therapeutics, PLC \| Receipt of Regulatory Approval in the United States
License Agreements
Amount of milestone payment			5,750,000
Amended License Agreement \| Horizon Therapeutics, PLC \| Receipt of Regulatory Approval outside the United States
License Agreements
Amount of milestone payment			$ 5,750,000